+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07167693

Phase 12 Study of Intravenous Arginine Hydrochloride to Boost Insulin and Speed Recovery in Adults with Ketone-Prone Type 2 Diabetes and Diabetic Ketoacidosis

Led by David K Carroll · Updated on 2026-02-12

60

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a form of diabetic ketoacidosis DKA that occurs in adults with a ketone-prone type 2 diabetes, where the pancreas temporarily reduces insulin production during severe high blood sugar. This study evaluates whether an intravenous infusion of arginine, an amino acid that can stimulate the pancreas to release insulin when glucose is high, can safely increase the bodys own insulin and speed recovery. The trial is a phase 12 randomized, double-blind, placebo-controlled study enrolling 60 adults with DKA in emergency departments. Participants will receive standard care for DKA, including fluids, insulin, and electrolyte management, plus a single 30-minute intravenous infusion of either arginine hydrochloride 30 grams or a placebo saline solution. The infusion starts as soon as possible after recognizing DKA, and both treatments are given under blinded conditions with matching procedures. Blood samples will be taken before and at 10, 30, and 90 minutes after infusion to measure insulin secretion and amino acid levels. During the study, participants will be closely monitored for safety, including vital signs and symptoms like flushing, nausea, or headache. Researchers will assess insulin secretion, ketone clearance, and total insulin use over 24 hours. Additional tests will explore blood markers and mitochondrial function in platelets. Follow-up will continue up to 90 days to check for any delayed effects. The total participation involves initial treatment and monitoring during hospitalization with follow-up contact afterward.

CONDITIONS

Brief Title

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Research Team

D

David K Carroll, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here